Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants

Cancer Research

Volumn 72, Issue 19, 2012, Pages 5035-5047

  Kluza, Jérome ^a   Corazao Rozas, Paola ^a   Touil, Yasmine ^a   Jendoubi, Manel ^a   Maire, Cyril ^a   Guerreschi, Pierre ^a   Jonneaux, Aurélie ^a   Ballot, Caroline ^a   Balayssac, Stéphane ^d   Valable, Samuel ^b,c   Corroyer Dulmont, Aurélien ^b,c   Bernaudin, Myriam ^b,c   Malet Martino, Myriam ^d   De Lassalle, ElisabethMartin ^a   Maboudou, Patrice ^e   Formstecher, Pierre ^a   Polakowska, Renata ^a   Mortier, Laurent ^a   Marchetti, Philippe ^a,e  

^a UNIV LILLE   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE CAEN   (France)

^d UPS)   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLOROACETIC ACID; ELESCLOMOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 3; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VEMURAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DICHLOROACETIC ACID; FEMALE; HL-60 CELLS; HUMANS; HYDRAZINES; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; MALE; MELANOMA; MICE; MICE, SCID; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867136838     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0979     Document Type: Article

References (49)

1. Fruehauf JP, Trapp V. Reactive oxygen species: an Achilles' heel of melanoma? Expert Rev Anticancer Ther 2008;8:1751-7.
2. 2-M cell cycle progression. Cancer Res2009;69:2647-54.
3. Ibañez I, Notcovich C, Policastro L, Durán H. Reactive oxygen species in the biology of melanoma. In: Tanaka Y, editor. Breakthroughs in melanoma research. Rijeka (Croatia): InTech; 2011. p. 1-32.
4. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-91.
5. Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, et al. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma. Chem Biol Interact 1998;111-112:277-305. (Pubitemid 28271951)
6. Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, et al. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS ONE 2012;7:e29798.
7. O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009;27:5452-8.
8. Kim J-W, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-30. (Pubitemid 44521105)
9. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 2011;286:42626-34.
10. Berry JD, Cook GJR. Positron emission tomography in oncology. Br Med Bull 2006;79-80:171-86.
11. Hersey P, Watts RN, Zhang XD, Hackett J. Metabolic approaches to treatment of melanoma. Clin Cancer Res 2009;15:6490-4.
12. Mills CN, Joshi SS, Niles RM. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol Cancer 2009;8:104.
13. Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 2010;29:227-36.
14. Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, et al. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 2009;69: 616-24.
15. Spinella F, Rosano L, Di Castro V, Decandia S, Nicotra MR, Natali PG, et al. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1 in human melanoma cells. Cancer Res 2007;67:1725-34. (Pubitemid 46383399)
16. Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002;16:1453-5.
17. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A sumoylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480:94-8.
18. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, et al. Mutant V600E BRAF increases hypoxia inducible factor-1 alpha expression in melanoma. Cancer Res 2007;67:3177-84. (Pubitemid 46724855)
19. Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 2012;25:375-83.
20. Semenza GL. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta 2011;1813:1263-8.
21. Wise DR, Ward PS, Shay JES, Cross JR, Gruber JJ, Sachdeva UM, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 2011;108:19611-6.
22. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005;65:3336-46. (Pubitemid 40524618)
23. Cormier CY, Mohr SE, Zuo D, Hu Y, Rolfs A, Kramer J, et al. Protein structure initiative material repository: an open shared public resource of structural genomics plasmids for the biological community. Nucleic Acids Res 2010;38:D743-9.
24. Ballot C, Kluza J, Lancel S, Martoriati A, Hassoun SM, Mortier L, et al. Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis 2010;15:769-81.
25. Kluza J, Jendoubi M, Ballot C, Dammak A, Jonneaux A, Idziorek T, et al. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS ONE 2011;6:e21924.
26. Beckonert O, Keun HC, Ebbels TMD, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007;2:2692-703.
27. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008;283:28106-14.
28. Moreno-Sánchez R, Saavedra E, Rodríguez-Enríquez S, Gallardo-Pérez JC, Quezada H, Westerhoff HV. Metabolic control analysisindicates a change of strategy in the treatment of cancer. Mitochondrion 2010;10:626-39.
29. Berridge MV, Herst PM, Tan AS. Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion 2010;10:584-8.
30. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
31. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008;8:705-13.
32. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff A-K. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010;46:1159-69.
33. Yeo E-J, Chun Y-S, Cho Y-S, Kim J, Lee J-C, Kim M-S, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25. (Pubitemid 36511622)
34. Fukuda R, Zhang H, Kim J-W, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007;129:111-22. (Pubitemid 46507584)
35. Semenza GL. Regulation of cancer cell metabolismby hypoxia-inducible factor 1. Semin Cancer Biol 2009;19:12-6.
36. Heumüller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schröder K, et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008;51:211-7. (Pubitemid 351159930)
37. Yang C, Sudderth J, Dang T, Bachoo RM, Bachoo RG, McDonald JG, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009;69:7986-93.
38. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Matés JM, et al.Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A 2011;108:8674-9.
39. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
40. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006;9:425-34. (Pubitemid 43832190)
41. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51. (Pubitemid 46054520)
42. Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y. A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers. PLoS ONE 2012;7:e30750.
43. Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki T. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 2005;96:394-402. (Pubitemid 41179740)
44. Baker JC, Yan X, Peng T, Kasten S, Roche TE. Marked differences between two isoforms of human pyruvate dehydrogenase kinase. J Biol Chem 2000;275:15773-81. (Pubitemid 30366876)
45. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002;277:23111-5. (Pubitemid 34952134)
46. Garber K. Oncology's energetic pipeline. Nat Biotechnol 2010;28:888-91.
47. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998;329:191-6. (Pubitemid 28022308)
48. Kim J-W, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85.
49. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006;3:187-97.